Neuronetics Posts Better Than Expected Q4 Results Despite Lower NeuroStar Therapy System Sales

Neuronetics Inc STIM reported Q4 FY21 sales of $15.02 million, down 4% Y/Y, exceeding previously issued guidance of $13.0 million - $14.0 million and the consensus of $14.43 million.

  • U.S. revenue decreased by 3% during the quarter, and international revenue decreased by 13% Y/Y due to lower NeuroStar Advanced Therapy System sales and treatment session revenue, respectively.
  • U.S. NeuroStar Advanced Therapy System revenue was $2.8 million, down 22%. The company shipped 48 units.
  • U.S. treatment session revenue was $11.2 million, +2%, and session revenue per active site was $12,183 compared to $12,133 during Q4 FY20.
  • The gross margin improved 60 basis points to 76.4%, primarily due to higher average sales prices of NeuroStar Advanced Therapy System units and a higher mix of treatment session revenue.
  • The company posted an EPS loss of $(0.29), beating the consensus of $(0.32), compared to $(0.19) a year ago.
  • Guidance: Neuronetics expects FY22 sales of $58 million - $62 million, compared to the consensus of $61.4 million. It expects FY22 total operating expenses to be $86.0 million - $90.0 million.
  • For Q1 FY22, the company expects sales of $13 million - $14 million, versus the consensus of $13.67 million.
  • Price Action: STIM shares are up 5.28% at $2.99 during the market session on the last check Tuesday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: EarningsNewsPenny StocksGuidanceHealth CareMoversTrading IdeasGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!